Lynx1 Capital Management LP - 31 May 2023 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
10%+ Owner
Signature
Lynx1 Capital Management LP, By: Lynx1 Capital Management GP LLC, its general partner, By: /s/ Weston Nichols, Sole Member
Issuer symbol
TCRX
Transactions as of
31 May 2023
Net transactions value
-$63,952
Form type
4
Filing time
02 Jun 2023, 17:35:20 UTC
Next filing
23 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRX Common stock, $0.0001 par value per share Common Stock Sale $25,148 -10,000 -0.19% $2.51 5,240,000 31 May 2023 See footnote F1
transaction TCRX Common Stock Sale $37,802 -15,000 -0.29% $2.52 5,225,000 31 May 2023 See footnote F1
transaction TCRX Common Stock Sale $1,003 -400 -0.01% $2.51 5,224,600 31 May 2023 See footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.